Multicycle [177Lu]Lu-PSMA-617 and pembrolizumab showed encouraging activity with manageable toxicity that was consistent with [177Lu]Lu-PSMA-617 or pembrolizumab, and the combination might provide durable clinical benefit in a subset of patients.
[Articles] [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
The Lancet Oncology | | Shahneen Sandhu, Anthony M Joshua, Louise Emmett, Mathias Bressel, Angelyn Anton, Lavinia Spain, Lisa G Horvath, Anupama Pasam, Sofie H Tolmeijer, Timothy J Akhurst, Ramin Alipour, Patricia Banks, James P Buteau, Erin Cassidy, Megan Crumbaker, Nattakorn Dhiantravan, Wen Xu, Joanna Chan, Nadia Hitchen, Mark Scalzo, Aravind S Ravi Kumar, Grace Kong, Roslyn Wallace, Narelle Williams, Scott Williams, Nicole M Haynes, Paul Neeson, Alexander W Wyatt, Rodney J Hicks, Michael S Hofman
Topics: prostate-cancer, immunotherapy, clinical-trials, research